ScripXiamen Amoytop Biotech, a Chinese biopharma focused on liver diseases and oncology, has stood out among its peers by becoming the first in years to acquire a pre-revenue compatriot biotech company. Sh
ScripDomestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and resea
ScripChinese biotechs once aspired to launching their products in the US and listing on Nasdaq as their ultimate achievements, but now many are turning more attention to their home turf and the Shanghai St
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, HanAll Co-Invest In Vinc